Mirikizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Interleukin 23 |
| Clinical data | |
| Trade names | Omvoh |
| Other names | LY3074828, Mirikizumab-mrkz |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6380H9842N1686O2004S48 |
| Molar mass | 143767.59 g·mol−1 |
Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis.[5] It is designed to attach to interleukin-23 (IL-23) and block its activity.[5]
The most common side effects include upper respiratory tract infections (nose and throat infections), headache, rash and reactions at the site of injection (when given by injection under the skin).[5]
Mirikizumab was approved for medical use in the European Union in May 2023,[5] and in the United States in October 2023.[7][8][9]
- ^ a b "Omvoh APMDS". Therapeutic Goods Administration (TGA). 11 October 2023. Archived from the original on 2 January 2024. Retrieved 7 March 2024.
- ^ "Details for: Omvoh". Drug and Health Products Portal. 5 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.
- ^ "Omvoh- mirikizumab-mrkz injection, solution". DailyMed. 31 October 2023. Archived from the original on 8 November 2023. Retrieved 8 November 2023.
- ^ a b c d e "Omvoh EPAR". European Medicines Agency. 8 June 2023. Archived from the original on 8 June 2023. Retrieved 8 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Omvoh". Union Register of medicinal products. 30 May 2023. Retrieved 6 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 26 October 2023. Archived from the original on 21 January 2023. Retrieved 30 October 2023.
- ^ "Eli Lilly's Omvoh granted FDA approval for ulcerative colitis". PMLive. 27 October 2023. Archived from the original on 30 October 2023. Retrieved 30 October 2023.
- ^ "FDA Approves Lilly's Omvoh (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis" (Press release). Eli Lilly and Company. Archived from the original on 30 October 2023. Retrieved 30 October 2023 – via PR Newswire.